ZEALAND PHARMA/S (NASDAQ:ZEAL) reached a new 52-week high during trading on Wednesday . The stock traded as high as $24.96 and last traded at $24.87, with a volume of 677 shares. The stock had previously closed at $24.87.
Several research analysts have commented on the stock. Morgan Stanley boosted their price target on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Zacks Investment Research downgraded shares of ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a research report on Saturday. TheStreet downgraded shares of ZEALAND PHARMA/S from a “c” rating to a “d+” rating in a research report on Friday, August 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 price objective (up previously from $29.00) on shares of ZEALAND PHARMA/S in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $27.33.
The firm has a market cap of $765.75 million, a PE ratio of 8.29 and a beta of 1.98. The firm’s 50-day moving average price is $21.83 and its two-hundred day moving average price is $20.23.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.10). The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $7.50 million. On average, research analysts expect that ZEALAND PHARMA/S will post -2.22 EPS for the current year.
An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. Susquehanna International Group LLP acquired a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 15,348 shares of the company’s stock, valued at approximately $331,000. Institutional investors and hedge funds own 9.38% of the company’s stock.
ZEALAND PHARMA/S Company Profile (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
See Also: Balanced Fund
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.